Comparative effectiveness is attracting top dollars — and thus hot debate — in the US right now. With over a billion dollars allocated to comparative effectiveness initiatives in the US by the American Recovery and Reinvestment Act, this is clearly a key element of US health reform.
What does it mean for manufacturers and stakeholders in the pharma and device industries? Certainly a profound re-shaping of the pricing and reimbursement landscape, as evidence is gathered on which services, drugs and devices work best — and are most cost-effective.
To find out more about how to understand and prepare for these developments, join FDC-Windhover, EuroPharma Today and Sidley Austin LLP for a webinar on April 21, 2009, live from Washington, DC and London.
Our speakers will be taking a look at what lessons can be drawn from other countries that have been designing and applying comparative effectiveness techniques for many years. In particular, we’ll be putting the spotlight on the United Kingdom’s renowned National Institute for Clinical Excellence (NICE). NICE assesses both the clinical- and cost-effectiveness of new and existing medicines, procedures, and technologies. Its decisions are critical in determining whether a drug or technology is reimbursed by the National Health Service — and thus in determining that product’s commercial success in the UK.
For more information, and to register, visit: http://www.windhover.com/ezine/html/ac0409-2-LP.htm
